Clinical Trial Update: Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating combined FDG-PET and 123I-iodometomidate imaging for adrenal neoplasia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenal Neoplasia

Drugs mentioned

• Fluorodeoxyglucose (FDG) (Fluorodeoxyglucose)
• Iodometomidate (I-123) (iodometomidate)

Snippet

Sponsor: Wuerzburg University Hospital | Conditions: Adrenal Neoplasia | Phase 3 | Status: TERMINATED